Podcasts about Lung cancer screening

Your primary care provider is doing their best. But there's something they may not be telling you — not because they're hiding it, but because they simply can't know everything.In this episode of Your Health University, Jamie Preston sits down with Scott Middleton — Founder and Chief Disruption Officer of Your Health — to talk about one of the most underutilized parts of the American healthcare system: specialty care. Scott shares real stories from the field that will make you rethink what you expect from your next appointment, including a patient who had been living in a nursing home for years without ever being offered a weight-loss medication that was available to her, and a lawsuit that turned on a single chest x-ray that no one thought to order.What you'll learn in this episode:Why your primary care provider legally cannot keep up with every new medication, treatment, and specialist recommendation — and what to do about itWhat GLP-1 medications are, who qualifies, and why so many eligible patients are never told they existThe standard of care around lung cancer screening for smokers — and why not knowing this can have life-altering consequencesHow to ask for a specialist referral (and what happens if your provider pushes back)Why behavioral health is one of the most under-accessed specialties in America — and how to change that for yourselfWhat "integrated care" actually looks like when it works — and what you deserve to expect from your healthcare teamYou are the CEO of your own health. This episode gives you tools to act like it. www.YourHealth.Org

Most healthcare organizations know specialty care matters. Almost none of them are actually using it at the level their patients need.In this episode of The Disrupted Podcast, Jamie Preston sits down with Scott Middleton — Founder and Chief Disruption Officer of Your Health — for an unfiltered look at one of the most critical gaps in care delivery: specialty services. Your Health currently routes about 10% of its patient appointments through specialty providers. The national average is 20%. Scott makes the case — with real stories from nursing homes, lawsuits, and the road across South Georgia — that closing that gap isn't just a clinical priority, it's a survival strategy.What you'll hear in this episode:Why a 400-pound patient in a nursing home had never been offered a GLP-1 for weight loss — and what that reveals about how providers think about specialtyThe exact communication chain (DPH → EDCS → Care Manager → Provider) and precisely where it breaks downHow 80% of Your Health patients have behavioral health needs while psych providers sit with open schedules — and how to fix that paradoxWhy texts and emails don't cut it in care coordination — and why voice-to-voice is the only real standardThe lawsuit that should have been prevented with a single chest x-ray, and what it means for provider accountability going forwardWhy Scott banned the word "no" inside Your Health — and the mindset shift that comes with replacing itSpecialty is what separates Your Health from every other provider in the market. If you're a DPH, a care manager, or a provider inside this system — this episode is for you. If you're a healthcare leader watching specialty care fall through the cracks anywhere, it might be for you too. www.YourHealth.Org

Stephanie A. Robinson, PhD, and Renda Soylemez Wiener, MD, MPH, join CHEST® Journal Podcast Moderator Alice Gallo De Moraes, MD, FCCP, to discuss their research into how the method of shared decision-making, in-person or telehealth, affects patients' perceptions of quality of shared decision-making for lung cancer screening. DOI: 10.1016/j.chest.2026.03.034 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine. 

My name is Sally Block, the MJA's news and online editor.“The MJA acknowledges the Traditional Owners and Custodians of the land on which we live and work across Australia.  This podcast was recorded on the lands of the Wangal people. I pay my respects to their Elders past and present.”The lung cancer screening program was introduced in July last year, designed to help with early intervention for Australia's deadliest cancer. So how's it faring?To discuss this, our special guest today is Professor Fraser Brims who is a consultant respiratory physician at St Charles Gairdener Hospital and Curtin University in Perth.He has written a perspective for the MJA on the program calling for more investment so it can reach it's full potential. He joins me on this podcast.

People with a history of tobacco smoking are recommended to have screening CT for lung cancer, but many of them choose not to be screened. A new study looks at the ability of a blood test to discern who is … Can a blood test improve lung cancer screening? Elizabeth Tracey reports Read More »

In a special edition of the This Week in Global Development podcast, Devex cofounder and Executive Vice President Alan Robbins sits down with Brazilian thoracic surgeon Dr. Ricardo Sales do Santos to discuss a revolutionary approach to tackling lung cancer in medically underserved communities in Brazil. As the most lethal form of cancer globally, lung cancer often goes undetected until its final stages, but Dr. Santos and the Bristol Myers Squibb Foundation are working to change that narrative through a combination of mobile technology and local capacity building. By bringing advanced CT scanning units directly into high-risk, low-income communities, they are catching tumors when they are small and potentially curable, fundamentally shifting the odds for thousands of patients. The conversation also touches on the logistical and cultural hurdles of delivering specialized oncology care to remote areas. Dr. Santos highlights the importance of “bringing the clinic to the patient,” utilizing mobile CT units and telemedicine to bridge the gap in healthcare access. Beyond the technology, the success of the program relies heavily on empowering local health workers and community members to recognize early cancer warning signs and overcome the stigma associated with a cancer diagnosis. This approach not only improves individual health outcomes but also strengthens the broader healthcare system, offering a scalable model for global health initiatives. To learn more about sustainable improvements in cancer care and get a compelling look at how local solutions can drive global change, listen to this special edition of This Week in Global Development. For more international development news, visit: http://www.devex.com Visit Strengthening Care Systems — a series raising awareness of the scale of the global lung cancer burden and the systems-level changes required to address it: https://pages.devex.com/strengtheningcaresystems.html

Michell Futrell is the Director of Lung Cancer Screening, Programs and Initiatives at the LUNGevity Foundation. Its mission is to close the gap of the 85% that do not receive an early detection screening. You should listen to this episode of The Mark Bishop Show. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Michell Futrell is the Director of Lung Cancer Screening, Programs and Initiatives at the LUNGevity Foundation. Its mission is to close the gap of the 85% that do not receive an early detection screening. You should listen to this episode of The Mark Bishop Show. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Abbie Begnaud discusses the importance of lung cancer screening and evolving strategies to improve early detection among high-risk populations, including: Low-dose CT screening, which reduces lung cancer mortality by detecting cancers at earlier, more treatable stages Updated screening guidelines that have expanded eligibility Key challenges that impact screening participation, including awareness, access, and broader risk assessment Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenter: Abbie Begnaud, MD, FCCP Associate Professor of Medicine University of Minnesota Pulmonary, Critical Care, Allergy and Sleep Medicine Program Director, Interventional Pulmonology Fellowship University of Minnesota Health Lung Cancer Screening Program Link to full program:  Advancing the Early Detection of Lung Cancer: A Multipronged Educational Initiative to Elevate Evidence-Based Screening Practices | Decera Clinical Education Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CME credits: 0.25 Valid until: 03-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/first-5-minutes-empowering-shared-decisions-in-lung-cancer-screening/50985/ This episode focuses on improving lung cancer screening and early detection by helping primary care providers recognize eligible and high-risk patients, apply current screening guidelines, and engage patients in clear shared decision-making conversations. Speakers will explore why many patients who qualify for low-dose CT scan screening are still not screened. Learn practice strategies to help close preventable gaps in care, including identifying risk during routine visits, addressing patient concerns, ordering appropriate screening, and ensuring follow-up for findings such as pulmonary nodules. =

Host: Brett Bade, MD Guest: Michael Gieske, MD This episode focuses on improving lung cancer screening and early detection by helping primary care providers recognize eligible and high-risk patients, apply current screening guidelines, and engage patients in clear shared decision-making conversations. Speakers will explore why many patients who qualify for low-dose CT scan screening are still not screened. Learn practice strategies to help close preventable gaps in care, including identifying risk during routine visits, addressing patient concerns, ordering appropriate screening, and ensuring follow-up for findings such as pulmonary nodules.

Editor's Summary by Preeti Malani, MD, MSJ, and Tracy Lieu, MD, MPH, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from May 16-22, 2026.

"Skin reactions, such as redness, dryness, and just irritation of the skin, can occur. Since we're irradiating the lung, we can also cause a cough, and that's due to the inflammation from the radiation. Patients can also get esophagitis if the tumor that we're treating is close to the midline of the chest near the esophagus. And probably the most common side effect that we see is fatigue," ONS member Amy MacRostie, RN, OCN®, radiation oncology nurse at St. Charles Cancer Center in Bend, OR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation side effects in lung cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 8, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the side effects of radiation to treat lung cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 369: Lung Cancer Survivorship Considerations for Nurses Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities Episode 313: Cancer Symptom Management Basics: Other Pulmonary Complications Episode 295: Cancer Symptom Management Basics: Pulmonary Embolism, Pneumonitis, and Pleural Effusion ONS Voice article: Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Radiation Therapy Certificate™ ONS ROCN™ Certification Review™ ONS Radiation Learning Library ONS Guidelines™ and Symptom Intervention Resources National Comprehensive Cancer Network LUNGevity Foundation Inspire Lung Cancer Survivors Community To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The types of radiation that can be used are external beam radiation and stereotactic body radiation treatment, or SBRT. External beam radiation is often used in combination with other treatment modalities, like chemotherapy, immunotherapy, and targeted therapy, to treat these cancers. And SBRT is usually done solo, and it's a highly precise treatment for inoperable or early-stage lung cancers." TS 1:52 "[Physicians and] providers can also help prevent side effects by reducing the dose to the heart and reducing the dose to the good lung tissue, if you will, as much as they possibly can. And this is done using intensity-modulated techniques, or IMRT. And that's where the linear accelerator sculpts the radiation beams conforming to the shape of the tumor itself." TS 6:37 "I think overall cancer treatment can lead to decreased libido and decreased sexual interest. Depression and fear can definitely play a role in this. And with lung radiation, specifically, fatigue and possibly shortness of breath with the exertion may decrease sexual interest. Nurses and providers should support the patient in their desire or lack thereof in sexual activities. We should have open discussions … and these can take place with patients about intimacy and how that can be approached in a different way that can accommodate for the side effects that the patients might be experiencing." TS 8:57 "Post-radiation scans will be abnormal. Post-radiation imaging can be misread as a progression of disease or residual disease. And I tell patients, 'Don't panic. Talk to your radiation oncologist so they can read the imaging themselves and interpret the results.' Oftentimes what's read as progression is radiation treatment sequela of scarring or fibrosis." TS 11:25

Interview with Yifan Zheng, MD

Lung cancer is the deadliest cancer—but early screening can save lives. A survivor's story and expert insight show why getting checked now matters. Call 844-ALA-LUNG.

Omari Richins, MPH of Public Health Careers podcast talks with Dr. Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM. In this conversation, Dr. Lisa Carter-Bawa shares her journey as a cancer prevention scientist and nurse practitioner, discussing her multiracial identity, the importance of community engagement in public health, and her philosophy of leadership. She emphasizes the need for a return to one's authentic self rather than reinvention, the impact of stigma in healthcare, and the significance of trust in patient-provider relationships. Dr. Carter-Bawa also highlights her work in cancer prevention research and the integration of behavioral science into public health leadership. In this conversation, Dr. Lisa Carter-Bawa shares her journey from nursing to becoming a leader in public health and behavioral science. She discusses the importance of understanding the barriers to health screenings, particularly lung cancer screening, and emphasizes the need for awareness and education in communities. Dr. Carter-Bawa highlights her commitment to continuous learning and the role of informatics in public health. She reflects on her experiences as a leader in spaces not traditionally designed for her and the importance of community engagement in research. The conversation concludes with insights on the cost of leadership and the importance of self-acceptance.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GEE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 11, 2027.Real-World Strategies and Workflows for Lung Cancer Screening Success in Diverse Populations: Enhancing Vigilance to Increase Early Detection on the Front Lines of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GEE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 11, 2027.Real-World Strategies and Workflows for Lung Cancer Screening Success in Diverse Populations: Enhancing Vigilance to Increase Early Detection on the Front Lines of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GEE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 11, 2027.Real-World Strategies and Workflows for Lung Cancer Screening Success in Diverse Populations: Enhancing Vigilance to Increase Early Detection on the Front Lines of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GEE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 11, 2027.Real-World Strategies and Workflows for Lung Cancer Screening Success in Diverse Populations: Enhancing Vigilance to Increase Early Detection on the Front Lines of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GEE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 11, 2027.Real-World Strategies and Workflows for Lung Cancer Screening Success in Diverse Populations: Enhancing Vigilance to Increase Early Detection on the Front Lines of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GEE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 11, 2027.Real-World Strategies and Workflows for Lung Cancer Screening Success in Diverse Populations: Enhancing Vigilance to Increase Early Detection on the Front Lines of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GEE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 11, 2027.Real-World Strategies and Workflows for Lung Cancer Screening Success in Diverse Populations: Enhancing Vigilance to Increase Early Detection on the Front Lines of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GEE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 11, 2027.Real-World Strategies and Workflows for Lung Cancer Screening Success in Diverse Populations: Enhancing Vigilance to Increase Early Detection on the Front Lines of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GEE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 11, 2027.Real-World Strategies and Workflows for Lung Cancer Screening Success in Diverse Populations: Enhancing Vigilance to Increase Early Detection on the Front Lines of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GEE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 11, 2027.Real-World Strategies and Workflows for Lung Cancer Screening Success in Diverse Populations: Enhancing Vigilance to Increase Early Detection on the Front Lines of Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Karen J. Wernli, PhD, joins CHEST® Journal Podcast Moderator Gretchen Winter, MD, to discuss her research into additional health communication to improve patient knowledge of lung cancer screening timeliness.  DOI: 10.1016/j.chest.2025.07.4111 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.       Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA262015. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. 

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-464 Overview: Beyond detecting disease early, lung cancer screening provides an opportunity to encourage smoking cessation. In this episode, we review USPSTF guidelines, compare screening effectiveness, and explore how the use of a pulmonary function test (PFT) and a lung age estimator can help people who smoke better understand their risks and inspire behavior change. Episode resource links: USPSTF: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening BMJ (Clinical Research Ed.). 2008;336(7644):598-600. doi:10.1136/bmj.39503.582396.25. BMC Public Health. 2022;22(1):1164. doi:10.1186/s12889-022-13583-1. Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-464 Overview: Beyond detecting disease early, lung cancer screening provides an opportunity to encourage smoking cessation. In this episode, we review USPSTF guidelines, compare screening effectiveness, and explore how the use of a pulmonary function test (PFT) and a lung age estimator can help people who smoke better understand their risks and inspire behavior change. Episode resource links: USPSTF: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening BMJ (Clinical Research Ed.). 2008;336(7644):598-600. doi:10.1136/bmj.39503.582396.25. BMC Public Health. 2022;22(1):1164. doi:10.1186/s12889-022-13583-1. Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Lung cancer screening is one of the simplest tools available in cancer care, yet it remains widely underused. A low-dose CT scan takes just a few minutes and can detect lung cancer at its earliest and most treatable stages. Jim Pantelas is a Navy Veteran and a 20 plus year lung cancer survivor. He was diagnosed with stage 3B lung cancer at age 52, back when lung cancer screening was not available. Today, he is joining Dr. Drew Moghanaki, a thoracic oncology leader and VA physician, to deliver a clear message to Veterans and anyone with a smoking history. Get screened. Every year. Key Topics Discussed: How lung cancer can grow with no symptoms until it is advanced Why Veterans may face higher risk from airborne hazards and toxic exposures What screening is like and why it takes less than three minutes Why annual screening matters, not just one scan How early detection expands treatment options and improves outcomes How to access screening through the VA or through civilian healthcare Why screening is covered and cost should not stop you Featured Guests: Jim Pantelas, Navy Veteran, 20 plus Year Lung Cancer Survivor Dr. Drew Moghanaki, UCLA and VA Thoracic Oncology Leader Key Takeaway: Lung cancer is curable when caught early. If you are eligible, start screening at 50 and go every year. Resources mentioned in this episode: PACT Act Benefits and Eligibility: https://www.va.gov/resources/the-pact-act-and-your-va-benefits/ VA Lung Cancer Screening: https://www.prevention.va.gov/preventing_diseases/screening_for_lung_cancer.asp Airborne Hazards and Burn Pit Registry: https://www.publichealth.va.gov/exposures/burnpits/registry.asp LCFA Screening Information: https://lcfamerica.org/about-lung-cancer/detection/screening/  Show Notes | Transcript | Watch Video Hashtags: #LungCancer #VeteransHealth #CancerScreening #EarlyDetection #VAHealthcare #PACTAct #HopeWithAnswers #LCFA

Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from November 15-21 2025.

Full article: Real-World Use and Outcomes of Lung-RADS v1.1 Category 4B Versus Lung-RADS v2022 Category 0 for Suspected Infectious or Inflammatory Findings on Lung Cancer Screening CT How should radiologists handle suspected infectious or inflammatory findings on lung cancer screening CT? Brittany Miles, MD, talks with Randall Rosenblatt, MD, on the implications of Lung-RADS v2022 category 0 in this setting, based on the recent AJR article by Arora et al.

As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We're kicking off the 2025 NSCLC Creator Weekend™ series with an in-studio panel discussion on the multidisciplinary management of lung cancer. The panel includes experts from medical oncology, thoracic surgery, radiation oncology, and interventional pulmonology from major institutions in Los Angeles. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS They discuss the operation of tumor boards at their respective institutions, the impact of virtual meetings, optimal strategies for mediastinal staging, the management of early-stage lung cancer, and the emerging role of ablation therapy. The conversation dives into the complexities of treating patients with recurrence or metastatic disease, highlighting the importance of collaborative decision-making in navigating these challenging scenarios. The episode emphasizes the critical role of multidisciplinary tumor boards in providing informed, patient-centered care. --- TIMESTAMPS 00:00 - Introduction06:59 - Role of Pulmonologists in Tumor Boards12:08 - Importance of Tissue Diagnosis24:52 - Lung Cancer Screening and Stigma34:01 - Interventional Radiology and Biopsies46:21 - Challenges with Immunotherapy and Radiation53:44 - The Importance of Multidisciplinary Teams54:24 - Final Thoughts --- RESOURCES American Lung Association 2024 Datahttps://www.lung.org/getmedia/12020193-7fb3-46b8-8d78-0e5d9cd8f93c/SOLC-2024.pdf National Lung Screening Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1102873 Checkmate 816https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 PACIFIC Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1709937

"It's critical to identify those mutations found that are driving the cancer's growth and guide the personalized treatment based on those results. And important to remember, too, early testing is crucial for patients with non-small cell lung cancer (NSCLC). In studies, it has been found to be associated with improved survival outcomes and reduced mortality," ONS member Vicki Doctor, MS, BSN, BSW, RN, OCN®, precision medicine director at the City of Hope Atlanta, GA, Chicago, IL, and Phoenix, AZ, locations, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the oncology nurse's role in NSCLC biomarker testing. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly Oncology and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities Episode 238: Cancer Genomics for Every Oncology Nurse Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Only a Third of Patients With Advanced Cancer Get Biomarker Testing, Limiting Use of Potentially Effective Precision Therapies Precision Medicine in Lung Cancer: How Comprehensive Testing Optimizes Patient Outcomes Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Using Nurse Navigators to Improve Timeliness of Biomarker Testing for Non-Small Cell Lung Cancer Oncology Nursing Forum article: Precision Medicine Testing and Disparities in Health Care for Individuals With Non-Small Cell Lung Cancer: A Narrative Review Other ONS resources: Best Practices for Biomarker Testing in Non-Small Cell Lung Cancer: A Case Study Genomics and Precision Oncology Learning Library Genomics Case Study: Precision Medicine in the Setting of Metastatic Non-Small Cell Lung Cancer Biomarker Database (refine by non-small cell lung cancer) Genomic Biomarkers Huddle Card Targeted Therapy Huddle Card National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "These biomarkers are used to provide information about cancer's characteristics or behavior. In oncology precision medicine specifically, molecular tests can help with diagnosing a cancer that is maybe an unknown primary. It can help with monitoring response to therapy, detect recurrence of disease before other tests can find that, predict prognosis or how aggressive the cancer may be, and guide treatment decisions for targeted therapies." TS 3:14 "Some of the key biomarkers recommended by the National Comprehensive Cancer Network (NCCN) to be tested in patients who have NSCLC are EGFR, ALK, KRAS, BRAF, MET exon 14 skipping mutation, HER2 which is a protein expression from an ErbB protein, PD-L1 which is a protein expression that's used to guide immunotherapy choices, and then finally there are three fusions: ROS1, RET, and NTRK. [These] are pretty rare but really important to be tested for in patients who have NSCLC." TS 3:46 "Another important challenge for nurses related to this topic is that these results may not reveal a targeted mutation for the patient and that could be very disappointing. So, being able to provide that emotional support to a patient if they have that result … you can actually reinforce with them that if [they] go onto another treatment that the physician decides to put [them] on, the tumor can change. New pathogenic variants can develop based on the treatment that they're getting, and another test can be done. And maybe at that time—a new biomarker that could be targeted—we'd be seeing on the new test." TS 7:32  "Another circumstance we didn't talk about yet is that maybe the result came back saying that the quality was not sufficient. And sometimes that happens, but that doesn't mean that we're at the end of the road, necessarily. So, you could explain to the patient that that may mean that possibly, a new biopsy would be ordered by the physician. Or if a new biopsy or another tissue sample is not available, then maybe the physician would pivot to sending a blood specimen for the molecular testing. So that would definitely be a way [nurses] could support their patients." TS 11:52 "In the case of patients with NSCLC, early testing is so important. So, advocating for that prompt biomarker testing to be done, making sure that it's comprehensive, that it's actually looking for all of those—I think it was 12 biomarkers—that I mentioned earlier. That this testing is done as soon as possible after diagnosis or progression. Something that I talk about all the time—personalized care, precision medicine—really matters. So, tailoring treatments for patients based on the biology of the tumor that's driving the cancer's growth is really crucial if you're going to be working as an oncology nurse. Another crucial thing, because it's changing so quickly, is to stay informed." TS 16:23

Host: Jasmine T. Kency, M.D., Associate Professor of Internal Medicine and Pediatrics at the University of Mississippi Medical Center.Guest(s): Priyanka Senthil, CEO of American Lung Cancer Screening Initiative and Sam Schwartz, National Director of American Lung Cancer Screening InitiativeTopic: Lung cancer screenings and the upcoming Jackson Stronger Together Community Health FairEmail the show: remedy@mpbonline.org. If you enjoy listening to this podcast, please consider contributing to MPB. https://donate.mpbfoundation.org/mspb/podcast. Hosted on Acast. See acast.com/privacy for more information.

Dr. Faisal Khan explains what screening is available for lung cancer, who qualifies for a screening, and how often lung screening appointments should be made.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from October 18-24, 2025.

Lung cancer is the leading cause of cancer death in the United States for both men and women. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. This is because the disease shows no symptoms until it has progressed to advanced stages when it is very difficult to treat. The good news is that advances in imaging have made it possible to detect lung cancer early on, when treatment can be highly successful.The Eisenhower Lung Cancer Screening Program evaluates current and former smokers to determine their risk for lung cancer and provides assessment and evaluation for persons at risk for lung cancer.

Australia has its first new cancer screening programme in 20 years, this time for lung cancer. Today we'll be discussing this new programme in depth as well as the role of primary care and the supports available in delivering the programme.This podcast is Sponsored by the Australian Government National Lung Cancer Screening Program.Professor Vivienne Milch is Medical Director, at Cancer Australia. Professor Milch is also Medical Advisor to the Australian Commonwealth Department of Health, Disability and Ageing on cancer screening policy.Professor Milch holds a Master's degree in Health Policy and is an Adjunct Clinical Associate Professor in the School of Medicine, Sydney Campus at The University of Notre Dame, Australia and Professorial Fellow at the Caring Futures Institute at Flinders University in Adelaide. Prior to joining Cancer Australia, Professor Milch was a General Practitioner and clinical researcher at the Garvan Institute of Medical Research, Sydney. Relevant links: the Investigating Symptoms of Lung Cancer guide Healthcare Provider Toolkit The NLCSP website Program Guidelines GP guide resource Reducing stigma in the program Low-dose CT Scan request form eLearning modules developed by Lung Foundation Australia Actionable additional findings guidelines

Smoking rates are high in rural parts of Ohio, but screening for lung cancer there can be hard to come by. A new mobile unit aims to help.

Thoracic radiologists Jeffrey Kanne, Miranda Siemienowicz and Jonathan Chung discuss the current global status of lung cancer screening, offering tips and tricks for reading these studies. Meanwhile, Andrew and Frank talk about everything BUT pulmonary nodules: another shameful journal travesty, TB sniffer rats and ketamine epiphanies.   Lung cancer screening article ► https://radiopaedia.org/articles/lung-cancer-screening Retraction Watch - Tin Man Syndrome ► https://retractionwatch.com/2025/08/15/tin-man-syndrome-case-plagiarized-from-hoax-sleuths-say/ Those TB detecting rats ► https://apopo.org/what-we-do/detecting-tuberculosis Become a supporter ► https://radiopaedia.org/supporters Get an All-Access Pass ► https://radiopaedia.org/courses/all-access-course-pass Radiopaedia Community chat ► http://radiopaedia.org/chat Ideas and Feedback ► podcast@radiopaedia.org   The Reading Room is a radiology podcast intended primarily for radiologists, radiology registrars and residents. 

As natural thyroid ban looms, thyroid sufferers gird for battle with regulators; Rapid weight loss, muscle wasting—what to do? Could overuse of CT scans cause 100,000 extra cancers in the U.S.? Martha's Vineyard, Nantucket residents afflicted with tick-borne meat allergy; Beyond Meat headed for Chapter 11 bankruptcy; Searching for the causes of low iron.

Australia's newest cancer screening program began a fortnight ago. It's looking to detect our nation's deadliest cancer – lung cancer. 

Australians at higher risk of lung cancer are being urged to take advantage of a new screening program that has launched this month. The scan will be free for patients under Medicare bulk-billing through GPs, with eligibility to be determined by age - those between 50 and 70 - and smoking history. It is the first new national cancer screening program in nearly 20 years. Lung cancer is Australia's fifth most diagnosed cancer, but causes the greatest number of cancer deaths because it is often diagnosed too late. SBS's Biwa Kwan spoke with Anita Dessaix from the Cancer Council, about the at-risk groups the program is targeting; and the goal to prevent over 12,000 deaths over a decade

“Just remember that these patients, these are human beings who had lung cancer. It's a scary disease. And we don't want to just say, ‘Oh, well, that's a horrible disease. They probably won't do well.' These patients are living longer. Our treatments are better. And so no matter who they are, they have every chance of surviving long term for this,” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer survivorship. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 27, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer survivorship. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities ONS Voice articles: Nursing Considerations for Lung Cancer Survivorship Care Nurse-Led Survivorship Programs: Expert Advice to Help You Build Your Institution's Resources Oncology Nursing Forum articles: Empowering Lung Cancer Survivors in Post-Treatment Survivorship Care Using Participatory Action Research A Qualitative Cultural Sensitivity Assessment of the Breathe Easier Mobile Application for Lung Cancer Survivors and Their Families Exploring Stigma Among Lung Cancer Survivors: A Scoping Literature Review ONS Survivorship Care Plan Huddle Card ONS Survivorship Learning Library To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “For patients with stage I disease, they have a pretty good chance of getting to that five-year mark, somewhere probably in the 70%–80% range, depending on if you're stage IA or IB. Then it starts to drop obviously if you go up stages with patients.” TS 6:36 “Our radiation oncologists … and the dosimetrists in radiation oncology do a great job trying to line those beams up to minimize toxicity to those other vital organs. But we just can't always do that. You may see long-term fibrotic changes within the lungs. You could see cardiac damage over time. You can see esophagitis or [gastrointestinal] toxicity, particularly in the esophagus over time, post-radiation. And just the fact of having disease or cancer in the lungs, you can have breathing problems and pulmonary issues long term.” TS 10:37 “Part of survivorship in lung cancer is smoking and smoking cessation. I know it can be hard for people to quit, even people who had curative-intent treatment for their lung cancer—and so keeping up with smoking cessation. And that can be hard again if you don't have access to a smoking cessation specialty or if you live with other people who smoke and don't have really access to programs to help you quit and help you stay quitting.” TS 17:26 “I should talk about autoimmune diseases as part of immunotherapy. We give immunotherapy now in the curative setting preoperatively, postoperatively, post-chemoradiation, so they may get a year or so of immunotherapy. They may develop some sort of autoimmune toxicity from that. Usually that will go away once we stop the immunotherapy. But I've seen some things persist over time. That can go anywhere from like mild eczema that came about to things like more serious, like maybe lupus or scleroderma that may have developed as part of your immunotherapy. And we may stop the immunotherapy, but that may linger on.” TS 25:02  

“A lot of other disease sites, they have some targeted therapies, they have some immunotherapies [IO]. In lung cancer, we have it all. We have chemo. We have IO. We have targeted therapies. We have bispecific T-cell engagers. We have orals, IVs. I think it's just so important now that, particularly for lung cancer, you have to be well versed on all of these,” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer treatment. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 16, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer treatments. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episode: Episode 359: Lung Cancer Screening, Early Detection, and Disparities ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cisplatin Oncology Drug Reference Sheet: Lazertinib Oncology Drug Reference Sheet: Nivolumab and Hyaluronidase-Nvhy Oncology Drug Reference Sheet: Fam-Trastuzumab Deruxtecan-Nxki Optimize Your Testing Strategy and Improve Patient Outcomes With NeoGenomics' Neo Comprehensive™–Solid Tumor Assay Clinical Journal of Oncology Nursing article: Oncogenic-Directed Therapy for Advanced Non-Small Cell Lung Cancer: Implications for the Advanced Practice Nurse ONS Biomarker Database ONS video: What is the role of the KRAS biomarker in NSCLC? Biomarker Testing in Non-Small Cell Lung Cancer Discussion Tool ONS Huddle Cards: Checkpoint inhibitors External beam radiation Monoclonal antibodies Proton therapy To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Unfortunately, because lung cancer is pretty aggressive, we'll see lung cancer mostly in stage IV. So about 50%–55% of all cases are not caught until they are already metastatic, or stage IV. And then about another 25%–30% of cases are caught in stage III, which means they're locally advanced and often not resectable, but we do still treat that with curative intent with concurrent chemoradiation. And then 10%–20% of cases are found in the early stage, and that's stage I and II, where we can do surgical approaches.” TS 2:53 “The majority of radiation that you're going to see is for patients with stage III disease that's inoperable. At my institution, a lot of stage III is inoperable. Now, neoadjuvant immunotherapy has changed that a little bit. But if you have several big, bulky, mediastinal lymph nodes that makes you stage III, surgery is probably not going to be a great option. So we give curative-intent chemoradiation to these patients.” TS 10:51 “Oligoprogression would mean they have metastases but only to one site. And sometimes we will be aggressive with that. Particularly, there's good data, if the only site of progression is in the brain, we can do stereotactic radiation to the brain and then treat the chest with concurrent chemoradiation as a more definitive approach. But outside of that, the majority of stage IV lung cancer is going to be treated with systemic therapy.” TS 15:00 “It's important for nurses to know that there's a lot of different options now for treatment. Probably one of the most important things is making sure patients are aware of what their biomarker status is, what their PD-L1 expression level is, and make sure those tests have been done. … It's good that the patients understand that there's a myriad of options. And a lot of that depends on what we know about their cancer, and then that guides our treatment.” TS 31:05

In this episode, Dr. Mark Meeker, VP and Chief Medical Officer at OSF St. Mary and Holy Family Medical Centers, shares how OSF is using FirstLook Lung, a groundbreaking blood test, to enhance early lung cancer detection—dramatically improving survival outcomes and streamlining care pathways.

Episode 359: Lung Cancer Screening, Early Detection, and Disparities “I was actually speaking to a primary care audience back a few weeks ago, and we were talking about lung cancer screening. And they said, ‘Our patients, they don't want to do it.' And I said, ‘Do you remind them that lung cancer is curable?' Because everybody thinks it is a death sentence. But when you're talking about screening a patient, I think it's really important to say, ‘Listen, if we find this early, stage I or stage II, our chances of curing this and it never coming back again is upwards of 60% to 70%,'” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer screening. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 18, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer screening. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 313: Cancer Symptom Management Basics: Other Pulmonary Complications Episode 295: Cancer Symptom Management Basics: Pulmonary Embolism, Pneumonitis, and Pleural Effusion Episode 247: Tobacco Treatment for Patients With Cancer ONS Voice articles: Lung Cancer Screening and Early Detection Drastically Improves Survival Rates Pack-Year History Is a Biased and Inadequate Criterion for Lung Cancer Screening Eligibility, Researchers Say CMS Expands Eligibility Criteria for Lung Cancer Screening With Low-Dose Computed Tomography Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Clinical Journal of Oncology Nursing articles: Nurse-Led Tobacco Cessation for Veterans Using Motivational Interviewing in a Lung Cancer Screening Program Identifying Primary Care Patients at High Risk for Lung Cancer: A Quality Improvement Study Oncology Nursing Forum article: Patient–Provider Discussion About Lung Cancer Screening Is Related to Smoking Quit Attempts in Smokers ONS Tobacco, E-Cigarettes, and Vaping Learning Library American Cancer Society Lung Cancer Screening Guidelines American Lung Association lung cancer resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Unfortunately, the current state of lung cancer screening is pretty low. Our rate of uptake in eligible patients is somewhere between 6% and 20%. And that falls much further below what we see for screening, such as breast cancer screening, prostate cancer screening, and colorectal cancer screening. So certainly, we can do better.” TS 1:32 “If you quit more than 15 or 20 years, your risk of developing lung cancer at that point is significantly lower. And so that's why once patients have quit more than 15 years, they're actually not eligible for screening anymore—because their risk of developing lung cancer is dramatically reduced. And that takes into account when you are a primary care provider, pulmonary, whatever field you work in, and you are running a screening clinic each year that you screen the patient, you have to remind yourself when they quit smoking, because once they reach that 15 years, then they're no longer eligible for screening.” TS 5:17 “One of the strategies that they've used to get the word out is, I watch a lot of baseball. I love the Philadelphia Phillies, watch Phillies games. And so at least once a year, maybe even twice a year, they will take an inning of the baseball broadcast on TV and on the radio separately, and they will bring on either an oncologist or pulmonologist from one of the local cancer centers in our area, and the whole inning—between batters of course—they will talk about lung cancer screening and why it's beneficial.” TS 13:16 “Medicare always has its idiosyncrasies. So Medicare—I went over the rules with you, so the age, the smoking. They follow all of it, except they have a slight difference in age. They cover it for age 50 to 77, as opposed to 80.” TS 16:52 “I think just the other thing that people don't think about is that to go get a medical test done, no matter what test it is, typically people have to take time off of work. And it can be really hard to do that when you are relying on your job, maybe you don't have vacation time, maybe you have children at home that you need to get home to. When people are weighing the risk/benefit and thinking, ‘Well, I'd love to get screened for lung cancer, but I just can't find time to fit it into my schedule, and my job won't let me take off.' These are all things that we don't always think about if you have the luxury of just taking the day off.” TS 20:01

Less than 20% of patients eligible for lung cancer screening get screened in the US. A recent study examined whether adults eligible for lung cancer screening engage in screening for other types of cancer. Coauthor Chi-Fu Jeffrey Yang, MD, of Harvard Medical School joins JAMA Deputy Editor Tracy Lieu, MD, to discuss. Related Content: Preventive Health Care Use Among Adults Eligible for Lung Cancer Screening in the US